Similar examples of 'niche unmet needs' include the identification of biomarkers to assess the risk of malignancy for thyroid nodules, specifically those with indeterminate results after standard thyroid biopsy; identification of biomarkers to improve on PSA's specificity in screening (such as prostate cancer gene 3) [12]; or, following diagnosis of prostate cancer, identification of biomarkers that discern between indolent versus aggressive prostate cancers. The gene discussed is KLK3; the disease is prostate cancer.